{"id":"NCT03045406","sponsor":"Fadoi Foundation, Italy","briefTitle":"Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer","officialTitle":"Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-13","primaryCompletion":"2019-06-01","completion":"2019-12-01","firstPosted":"2017-02-07","resultsPosted":"2025-06-18","lastUpdate":"2025-06-24"},"enrollment":1170,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"Apixaban","otherNames":[]},{"type":"DRUG","name":"Dalteparin","otherNames":[]}],"arms":[{"label":"Apixaban","type":"EXPERIMENTAL"},{"label":"Dalteparin","type":"ACTIVE_COMPARATOR"}],"summary":"Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study","primaryOutcome":{"measure":"Recurrent Venous Thromboembolism","timeFrame":"6 months","effectByArm":[{"arm":"Apixaban","deltaMin":32,"sd":null},{"arm":"Dalteparin","deltaMin":46,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":127,"countries":["United States","Belgium","France","Germany","Israel","Italy","Netherlands","Poland","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["34382385","34260816","32223112"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":255,"n":576},"commonTop":["Epistaxis","Anaemia","Dyspnoea"]}}